Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Polly Burbidge"'
Autor:
Dr. Laura L Hammitt, MD, Rosie J Crane, MBBS, Angela Karani, BSc, Alex Mutuku, MSc, Susan C Morpeth, FRACP, Polly Burbidge, BSc, Prof. David Goldblatt, MB ChB, Tatu Kamau, MPH, Shahnaaz Sharif, MD, Neema Mturi, MRCPCH, Prof. J Anthony G Scott, FRCP
Publikováno v:
The Lancet Global Health, Vol 4, Iss 3, Pp e185-e194 (2016)
Background: Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series without a booster, was introduced into the childhood vaccination programme in Kenya in 2001. The duration of protection and need for a booster dose ar
Externí odkaz:
https://doaj.org/article/fb6be273a4874e1db40c7d004e5d4b43
Autor:
Lindsay R Grant, Sarah E O'Brien, Polly Burbidge, Mitch Haston, Marta Zancolli, Lucy Cowell, Marina Johnson, Robert C Weatherholtz, Raymond Reid, Mathuram Santosham, Katherine L O'Brien, David Goldblatt
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74906 (2013)
Protection against disease or colonization from serotypes related to those in pneumococcal conjugate vaccines (i.e. cross-protection) vary by serotype; the basis for this variation is not understood. The 13-valent pneumococcal conjugate vaccine (PCV1
Externí odkaz:
https://doaj.org/article/c7a1430325474c2c883b8fd51ff2c600
Autor:
Sue Hill, Michael Joachim, Yin Pang, Ann McIlgorm, Jeremy S. Brown, Camilo A. Colaco, Kate A. Dalton, Christopher Bailey, David Goldblatt, Claire Entwisle, Polly Burbidge
Publikováno v:
Vaccine. 36(29)
Streptococcus pneumoniae has multiple protein antigens on the surface in addition to the serotype specific polysaccharide capsule antigen. Whilst the capsule antigen is the target of the polysaccharide vaccines, bacterial proteins can also act as tar
Autor:
David, Goldblatt, Jo, Southern, Nick J, Andrews, Polly, Burbidge, Jo, Partington, Lucy, Roalfe, Marta, Valente Pinto, Vasilli, Thalasselis, Emma, Plested, Hayley, Richardson, Matthew D, Snape, Elizabeth, Miller
Publikováno v:
The Lancet. Infectious Diseases
Background: Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare
Autor:
Lindsay R. Grant, Raymond Reid, Mitch Haston, David Goldblatt, Mathuram Santosham, Katherine L. O'Brien, Marina Johnson, Polly Burbidge
Publikováno v:
Pediatric Infectious Disease Journal. 34:e138-e142
Pneumococcal conjugate vaccine (PCV) induces protective anticapsular IgG, which mediates disease immunity. IgG persistence may influence long-term protection.An observational, prospective, longitudinal study of nasopharyngeal carriage among American
Autor:
Helen Findlow, Nick Andrews, Elizabeth Miller, Anna England, David Goldblatt, Pauline Waight, Xilian Bai, Bassam Hallis, Ray Borrow, Polly Burbidge, Shamez N Ladhani, Mary Matheson, Emma Pearce
Publikováno v:
Vaccine. 33:648-655
An open, non-randomised study was undertaken in England during 2011-12 to evaluate vaccine antibody responses in infants after completion of the routine primary infant immunisation schedule, which included two doses of meningococcal group C (MenC) co
Publikováno v:
The Pediatric infectious disease journal. 36(12)
Maternal immunization with a tetanus, diphtheria and acellular pertussis (Tdap) vaccine may blunt infant pneumococcal immune responses after a primary series of vaccines.As part of a prospective controlled cohort trial of Tdap (Boostrix; GSK Biologic
Autor:
Shahnaaz K Sharif, David Goldblatt, Rosie J. Crane, Susan C. Morpeth, Neema Mturi, Laura L. Hammitt, Alex Mutuku, J. Anthony G. Scott, Tatu Kamau, Angela Karani, Polly Burbidge
Publikováno v:
The Lancet Global Health, Vol 4, Iss 3, Pp e185-e194 (2016)
The Lancet. Global Health
The Lancet. Global Health
Summary Background Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series without a booster, was introduced into the childhood vaccination programme in Kenya in 2001. The duration of protection and need for a booster
Autor:
Gayatri Amirthalingam, David Goldblatt, Jo Southern, Pauline Waight, Shamez N Ladhani, Mary Matheson, Vasili Thalasselis, Bassam Hallis, Helen Findlow, Christine E. Jones, Ray Borrow, Paul T. Heath, Anna England, Xilian Bai, Polly Burbidge, Nick Andrews, Elizabeth Miller
INTRODUCTION: In England, antenatal pertussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertussis/inactivated-polio (TdaP5/IPV) vaccine was introduced in October 2012. We assessed infant responses to antigens in the mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4b3faeeb943d3c5102fa91ed8a8e905
https://openaccess.sgul.ac.uk/id/eprint/108074/1/Pertussis_revise7.docx
https://openaccess.sgul.ac.uk/id/eprint/108074/1/Pertussis_revise7.docx
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Immunization of Kenyan newborns with 7-valent pneumococcal conjugate vaccine is safe and immunogenic. Compared with the Expanded Programme on Immunization schedule beginning at 6 weeks, it stimulates similar antibody concentrations at 18 weeks and in